[ad_1]
Novavax RSV vaccine fails advanced study; shares down 63% before marketing
Novavax (NVAX) is ready for significant pre-market marketing, following the results of a Phase 3 clinical trial, Prepare, evaluating ResVax, an alumin.
View full coverage on Google News
[ad_2]
Source link